CRYOFOCUS-B: The asthma cryoablation system has received breakthrough medical device designation from the U.S. Food and Drug Administration
I'm PortAI, I can summarize articles.
CRYOFOCUS-B announced that its asthma cryoablation system has received breakthrough medical device designation from the U.S. Food and Drug Administration. The system is independently developed and aims to treat moderate to severe asthma by using cryoablation technology to disrupt the pulmonary vagus nerve, reducing the release of acetylcholine and mucus secretion, thereby effectively treating asthma
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments